S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up
S&P 500   4,550.43
DOW   35,333.47
QQQ   389.17
Is Microsoft the NVIDIA Killer? 
Important info on NVDA trade (Ad)
Give up the OPEC fight with these 3 stocks, Buffett-certified
AI revolution: 3 stocks set to soar as technology evolves
Important info on NVDA trade (Ad)
3 reasons a squeeze could be in Paramount's coming attractions
BellRing Brands gets pumped on the Ozempic weight-loss trend
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
Americans Ditched Big Cities During the Pandemic. Now Many Are Regretting It.
At these prices, the only way these stocks can move is up

Aptevo Therapeutics Stock Price, News & Analysis (NASDAQ:APVO)

$0.18
-0.01 (-5.15%)
(As of 11/27/2023 ET)
Compare
Today's Range
$0.18
$0.19
50-Day Range
$0.18
$0.38
52-Week Range
$0.15
$7.20
Volume
216,131 shs
Average Volume
252,463 shs
Market Capitalization
$3.25 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Aptevo Therapeutics MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.59% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.82mentions of Aptevo Therapeutics in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.78) to ($1.33) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.70 out of 5 stars


APVO stock logo

About Aptevo Therapeutics Stock (NASDAQ:APVO)

Aptevo Therapeutics Inc., a clinical-stage biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company's lead clinical candidates are APVO436, a bispecific T-cell engaging antibody candidate that is in Phase 1b clinical trial for acute myelogenous leukemia and myelodysplastic syndromes; and. ALG.APV-527, an investigational bispecific ADAPTIR candidate that features a mechanism of action to target 4-1BB (CD137) and 5T4, a tumor antigen expressed in various types of cancers. Its preclinical candidates include APVO603, a dual agonist bispecific antibody to target 4-1BB and OX40; APVO711, a dual mechanism bispecific ADAPTIR candidate designed to provide synergistic stimulation of CD40 on antigen presenting cells; and APVO442, a bispecific candidate based on the ADAPTIR-FLEX platform technology to enhance biodistribution of drugs to PSMA positive tumors for treatment of prostate cancer. The company has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.

APVO Stock Price History

APVO Stock News Headlines

Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
Aptevo Therapeutics GAAP EPS of -$0.50
Aptevo to Present at Bio-Europe Conference
Important info on NVDA trade
Today, I’m pulling back the curtain on my all-new Everyday Income project. A way for everyday folks to target a couple hundred bucks or more every single day the markets are open… Without breaking a sweat!
Aptevo Therapeutics Inc
APVO - Aptevo Therapeutics Inc.
Short Volatility Alert: Aptevo Therapeutic
See More Headlines
Receive APVO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Aptevo Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/14/2023
Today
11/27/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
4/04/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:APVO
Employees
45
Year Founded
2016

Profitability

Net Income
$8.03 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$3.11 million
Book Value
$2.78 per share

Miscellaneous

Free Float
16,965,000
Market Cap
$3.25 million
Optionable
Not Optionable
Beta
5.25

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. Marvin L. White (Age 61)
    President, CEO & Director
    Comp: $892.86k
  • Mr. Jeffrey G. Lamothe CA (Age 57)
    Executive VP & COO
    Comp: $691.37k
  • Ms. SoYoung Kwon J.D.
    LL.M., Senior VP, General Counsel, Business Development & Corporate Affairs
  • Ms. Daphne L. Taylor (Age 57)
    Senior VP & CFO
  • Dr. Jane A. Gross Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $515.17k
  • Dr. Dirk Huebner M.D. (Age 60)
    Chief Medical Officer














APVO Stock Analysis - Frequently Asked Questions

Should I buy or sell Aptevo Therapeutics stock right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aptevo Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" APVO shares.
View APVO analyst ratings
or view top-rated stocks.

How have APVO shares performed in 2023?

Aptevo Therapeutics' stock was trading at $2.32 at the start of the year. Since then, APVO shares have decreased by 92.1% and is now trading at $0.1843.
View the best growth stocks for 2023 here
.

When is Aptevo Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 4th 2024.
View our APVO earnings forecast
.

How were Aptevo Therapeutics' earnings last quarter?

Aptevo Therapeutics Inc. (NASDAQ:APVO) posted its earnings results on Tuesday, November, 14th. The biotechnology company reported ($0.50) EPS for the quarter, topping analysts' consensus estimates of ($0.64) by $0.14.

What other stocks do shareholders of Aptevo Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Aptevo Therapeutics investors own include Advanced Micro Devices (AMD), Amarin (AMRN), AVEO Pharmaceuticals (AVEO), Alibaba Group (BABA), Micron Technology (MU), OPKO Health (OPK), AbbVie (ABBV), Aurinia Pharmaceuticals (AUPH), BioXcel Therapeutics (BTAI) and T2 Biosystems (TTOO).

Who are Aptevo Therapeutics' major shareholders?

Aptevo Therapeutics' stock is owned by many different retail and institutional investors. Top institutional shareholders include Sabby Management LLC (11.58%), Armistice Capital LLC (10.72%) and Concourse Financial Group Securities Inc. (0.00%).
View institutional ownership trends
.

How do I buy shares of Aptevo Therapeutics?

Shares of APVO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:APVO) was last updated on 11/28/2023 by MarketBeat.com Staff

My Account -